Best for Injury Recovery

Teriparatide significantly accelerates fracture healing in humans, reducing time to union by 1.5–6 months and improving functional outcomes. Multiple RCTs and meta-analyses confirm efficacy, particularly for atypical femoral fractures and hip fractures, though some outcomes (complete healing rates) show inconsistent effects.

Creatine monohydrate shows probable benefit for injury recovery in humans, with evidence of improved strength recovery after ACL surgery and tendon injury rehabilitation, but efficacy is inconsistent across different injury types and not conclusively demonstrated in all contexts.

Ashwagandha shows probable efficacy for muscle strength and recovery in resistance training based on one well-designed human RCT, but evidence for broader injury recovery is limited to mechanistic studies in animal models and reviews. Human evidence is insufficient to establish proven efficacy across injury recovery generally.

SS-31 (elamipretide) shows probable efficacy for injury recovery in humans, with 2 small RCTs demonstrating improvements in renal function and mitochondrial protection during ischemia-reperfusion injury, supported by mechanistic evidence from animal models and in vitro studies. However, human evidence remains limited to small pilot trials without independent replication.

LL-37 shows probable efficacy for injury recovery based on multiple human studies and consistent animal data, but evidence is limited to 1 RCT and small observational cohorts. Clinical benefit is demonstrated in wound healing and tissue repair contexts, though effect sizes vary and independent replication is limited.

ARA-290 demonstrates probable efficacy for injury recovery based on 3 human RCTs showing improvements in nerve fiber regeneration, pain reduction, and functional capacity. However, sample sizes are small (n=28-64), studies are short-term (28 days), and results lack independent replication across different injury types.

Cerebrolysin shows probable efficacy for injury recovery, particularly in traumatic brain injury and stroke, supported by multiple human RCTs with consistent positive effects. However, sample sizes remain modest (n=30-142), and results have not been independently replicated across all injury types.

Ibutamoren shows modest efficacy for injury recovery in hip fracture patients, with some improvements in functional outcomes (gait speed) and bone turnover markers, but results are inconsistent across multiple measures and safety concerns have emerged during trials.

Cortexin shows probable efficacy for traumatic brain injury recovery in humans based on one small RCT, with additional animal evidence of neural tissue protection. However, efficacy remains unproven due to limited human data and lack of independent replication.

Magnesium supplementation shows probable efficacy for injury recovery, particularly for wound healing in diabetic foot ulcers and nerve regeneration in animal models. However, evidence remains limited to small human RCTs and animal studies; bone fracture healing data in humans is mixed and underpowered.

NAC shows probable efficacy for injury recovery across multiple wound healing and tissue repair models, with consistent positive results in animal studies and emerging human evidence. However, human RCTs remain limited in number and sample size, and clinical meaningfulness varies across injury types.

Vitamin D3 shows probable benefits for injury recovery, particularly for bone healing and wound repair, based on multiple human RCTs. However, evidence is mixed across different recovery contexts and effect sizes vary considerably, preventing a higher tier classification.

Zinc supplementation shows probable efficacy for injury recovery, particularly wound healing in specific populations (pressure ulcers, diabetic foot ulcers, post-surgical wounds), supported by multiple human studies and meta-analyses. However, evidence quality is mixed with small sample sizes and inconsistent results across different injury types.

Curcumin shows probable efficacy for reducing exercise-induced muscle damage and delayed-onset muscle soreness (DOMS) in humans, supported by 2 meta-analyses and 2 small RCTs. However, evidence is limited by small sample sizes, short follow-up periods, and mixed results in field-based studies.

CoQ10 shows probable efficacy for injury recovery, with the strongest evidence in exercise-induced muscle damage and post-surgical wound healing. Human RCT data is limited (n=1 surgical study with 70 participants), but a 2025 meta-analysis of 17 trials demonstrates CoQ10 reduces muscle damage biomarkers (LDH, CK) and oxidative stress markers in athletes, though effect sizes are modest and evidence quality remains low to moderate.

Collagen peptides show probable benefits for injury recovery, particularly for muscle soreness and joint function, supported by multiple human studies and consistent mechanistic evidence. However, efficacy remains modest and inconsistently demonstrated across all recovery markers, with most human trials involving small sample sizes and short intervention periods.

Probiotics show probable efficacy for injury recovery, particularly for wound healing and post-surgical outcomes, supported by multiple human RCTs and meta-analyses. However, effects are inconsistent across injury types, effect sizes are modest, and most studies have limitations in design or sample size.

Melatonin shows probable efficacy for injury recovery based on 2 human RCTs and multiple animal studies, with demonstrated benefits for rehabilitation outcomes and sleep recovery post-injury. However, evidence is limited to specific injury types (COPD rehabilitation, stroke) and most mechanistic data comes from animal models.

Black seed oil (Nigella sativa) demonstrates probable efficacy for wound healing based on 2 human RCTs and multiple animal studies showing consistent improvements in wound closure and pain reduction. However, human evidence is limited to small samples and specific wound types (episiotomy, radiotherapy-induced salivary gland damage), so efficacy for broader 'injury recovery' remains incompletely proven.

Aged garlic extract (AGE) shows probable efficacy for injury recovery through improvements in microcirculation and wound healing, demonstrated in 3 human RCTs and several animal models. However, evidence is limited by small human sample sizes, modest effect sizes, and lack of independent replication across research groups.

Vitamin C shows probable efficacy for injury recovery, particularly for chronic foot ulcers and wound healing, with mechanistic support for collagen synthesis and immune function. However, evidence is limited by small RCT sample sizes, variable dosing protocols, and lack of independent replication across most study populations.

Vitamin B12 shows probable efficacy for peripheral nerve injury recovery and neuropathic pain based on multiple human studies, but evidence remains limited by small sample sizes, heterogeneous treatment regimens, and lack of large-scale RCTs. Most robust data exists for diabetic peripheral neuropathy and nerve regeneration, though clinical meaningfulness of improvements varies.

Copper supplementation shows probable efficacy for injury recovery in specific contexts (major burns, spinal cord injury), supported by 2 human RCTs and multiple observational studies in burn patients. However, evidence is limited by small sample sizes, narrow injury types studied, and inconsistent effects across different recovery mechanisms.

Boswellia serrata demonstrates probable efficacy for injury recovery in humans, supported by 3 RCTs and 2 observational studies showing improvements in fracture healing, soft tissue injuries, and pain/swelling outcomes. However, evidence remains limited by small sample sizes, heterogeneous injury types, and incomplete replication across independent research groups.

Pycnogenol shows probable efficacy for injury recovery, particularly for wound healing and nerve regeneration, supported by multiple human RCTs and consistent animal studies. However, evidence remains limited by small sample sizes, heterogeneous injury types, and lack of independent replication across all study types.

Beta-glucans show probable efficacy for injury recovery and wound healing based on multiple human and animal studies, with demonstrated effects on immune activation, macrophage function, and accelerated wound closure. However, evidence is limited to 1 human RCT and 2 observational studies; most data comes from animal models and mechanistic reviews.

Pomegranate extract shows probable efficacy for injury recovery in humans, with demonstrated benefits for post-exercise muscular recovery and strength restoration after eccentric exercise. Evidence is moderate but limited by small sample sizes and few independent replications.

Grape seed extract shows probable efficacy for injury recovery, particularly for wound healing and muscle recovery, based on multiple human RCTs and consistent animal studies. However, evidence remains limited by small sample sizes, heterogeneous outcome measures, and lack of large-scale replication.

Olive leaf extract (OLE) and its main compound oleuropein show promise for wound healing in both animal and human studies, with demonstrated effects on wound closure, collagen deposition, and tissue regeneration. However, evidence is limited to small human pilot/observational studies; only 2 human RCTs exist and neither directly measured primary wound healing outcomes.

Bromelain shows probable efficacy for injury recovery in humans, with multiple small-to-moderate RCTs and observational studies demonstrating pain reduction, edema management, and accelerated wound healing. However, evidence is limited by small sample sizes, inconsistent comparisons across studies, and lack of large-scale replication.

Whey protein shows probable efficacy for some aspects of injury recovery, particularly for accelerating satellite cell proliferation and strength recovery after eccentric muscle damage, but evidence is mixed with several null findings and inconsistent results across recovery metrics.

Hyaluronic acid combined with arthroscopic surgery shows probable efficacy for meniscal injury recovery in a meta-analysis of 11 RCTs, with improvements in pain, function, and joint mobility. However, evidence is primarily limited to intra-articular injection post-surgery; oral supplementation and isolated HA efficacy are poorly studied for injury recovery.

CDP-Choline shows probable efficacy for injury recovery, particularly in spinal cord and peripheral nerve injury in animal models and some human studies, but evidence in humans is mixed with inconsistent results across traumatic brain injury trials.

Ginkgo biloba shows probable efficacy for injury recovery across multiple human and animal studies, particularly for neurological injuries and stroke recovery, but evidence is limited by small human sample sizes, lack of large-scale RCTs, and predominance of animal data.

Uridine shows probable efficacy for injury recovery, supported by one human RCT demonstrating significant pain reduction in peripheral neuropathy and multiple consistent animal studies showing accelerated nerve and muscle regeneration. However, evidence is limited to a single open-label human trial and lacks independent replication in human populations.

Vinpocetine shows probable efficacy for injury recovery, particularly in ischemic stroke and vascular injury models, supported by one human RCT and multiple animal/observational studies demonstrating neuroprotective mechanisms. However, evidence is limited by small human sample sizes, lack of independent replication in humans, and mixed study designs that prevent definitive clinical conclusions.

L-glutamine shows probable benefits for injury recovery based on multiple human studies demonstrating improvements in wound healing, inflammatory markers, and hospital outcomes, but evidence is limited by small sample sizes and inconsistent study designs.

Acetyl-L-carnitine shows probable efficacy for nerve injury recovery in humans, with multiple small-to-moderate RCTs demonstrating pain reduction and improved nerve regeneration markers. However, evidence is limited by small sample sizes, short follow-up periods, and inconsistent functional outcome improvements.

HMB shows probable efficacy for injury recovery in specific clinical contexts—particularly for surgical wound healing and recovery in malnourished/compromised patients—but evidence is inconsistent and limited by small sample sizes and mixed results in athletic/muscle damage contexts.

Taurine shows probable efficacy for cardiac ischemia-reperfusion injury in human observational studies and consistent benefit in animal models, but human RCT evidence is sparse and most mechanistic support comes from controlled animal experiments rather than clinical trials.

BCAAs show probable benefit for traumatic brain injury recovery and delayed-onset muscle soreness (DOMS) in trained athletes, but efficacy is not conclusively proven. Results are mixed for general muscle injury recovery, with some studies showing no benefit.

L-arginine shows probable efficacy for injury recovery, particularly in burn wound healing and fracture healing, supported by multiple human studies and consistent animal data. However, evidence remains limited by small sample sizes, short follow-up periods, and mixed results in some populations.

Leucine supplementation shows probable benefit for skeletal muscle injury recovery in animal models and limited human studies, primarily through enhanced protein synthesis and reduced muscle atrophy markers. However, human evidence remains sparse and inconsistent, with one high-quality RCT showing no benefit during immobilization.

Abaloparatide shows probable efficacy for bone injury recovery based on multiple human case reports and animal studies demonstrating accelerated fracture and bone defect healing, but evidence is limited by small sample sizes, lack of large RCTs specifically testing fracture healing, and dependence on observational data.

Calcium supplementation shows moderate evidence for supporting bone health and reducing bone resorption markers during pregnancy, lactation, and in postmenopausal women, but evidence specifically for acute injury recovery is limited and mixed.

Vitamin B3 (nicotinamide) shows promising effects on muscle recovery and wound healing in humans, with one RCT demonstrating efficacy for skin cancer prevention via DNA repair. However, evidence remains limited by small sample sizes, mixed results in muscle recovery studies, and lack of large-scale human trials specifically targeting injury recovery.

Vitamin B6 shows promising effects on muscle recovery in humans, with one RCT demonstrating enhanced muscle stem cell activity and regeneration after eccentric exercise. However, evidence is limited to a single human trial with modest sample size, and efficacy for broader injury recovery remains unproven.

Vitamin A shows probable benefit for injury recovery, particularly for wound healing and tissue repair, supported by 1 human RCT demonstrating reduced renal scarring and improved UTI symptoms, plus mechanistic reviews and observational evidence. However, efficacy is not conclusively proven across diverse injury types, and most supporting evidence comes from animal studies or small human trials.

BPC-157 shows promising effects for injury recovery in extensive animal studies, but human evidence is extremely limited with only small pilot studies.

TB-500 shows promising wound healing and tissue repair effects in multiple animal models, but human evidence is extremely limited with only preliminary studies in specific conditions like cardiac injury and fat grafting.

GHK-Cu shows consistent mechanistic promise for injury recovery in animal models and cell culture, but human efficacy remains largely unproven. Only one human RCT exists (ACL reconstruction in rats, not humans despite the classification), demonstrating transient improvements that did not persist after treatment stopped.

Ipamorelin is theoretically relevant to injury recovery through growth hormone secretagogue mechanisms, but there are zero human clinical trials demonstrating actual efficacy for this goal. Current evidence consists only of mechanistic reviews citing animal and in-vitro data.

Semax shows neuroprotective effects and improves functional recovery after spinal cord injury in female mice through mechanisms involving oxidative stress reduction and ubiquitination pathways. However, no human clinical trials exist, and efficacy is demonstrated only in a single animal model study.

KPV demonstrates anti-inflammatory and wound-healing potential in animal models and cell-based assays, but human efficacy evidence is limited to a single observational study in chemotherapy-induced oral mucositis. Efficacy is plausible but not yet proven in humans.

Thymosin alpha-1 shows plausible mechanisms for injury recovery through angiogenesis and immune modulation in animal models and one human surgical trial, but human efficacy for injury recovery specifically remains unproven. Mixed results in observational COVID-19 studies suggest potential harm in critically ill patients.

MOTS-c shows promise for injury recovery in animal models and limited human data, with demonstrated effects on bone fracture healing, lung injury, and intervertebral disc degeneration. However, efficacy in humans remains largely unproven—only one small human observational study exists with no RCTs.

AOD-9604 shows plausible promise for injury recovery based on mechanistic theory and one small animal study, but no human clinical trials exist. Current evidence is insufficient to prove efficacy in humans.

Sermorelin (GHRH agonist) shows promise for injury recovery through animal and mechanistic studies demonstrating enhanced wound healing and cardiac repair, but human efficacy for injury recovery remains unproven with only 2 small human RCTs focused on cardiac outcomes rather than general injury recovery.

Tesamorelin has not been studied for injury recovery in humans. While mechanistic reviews suggest growth hormone secretagogues like tesamorelin may theoretically support tissue regeneration, this remains speculative with no clinical trial evidence for musculoskeletal injury recovery.

GHRP-2 shows promise for tendon-bone healing in a rat rotator cuff model, with improvements in histologic scores, bone mineral density, and biomechanical properties. However, evidence is limited to one animal study and a review; no human clinical trials have demonstrated efficacy for injury recovery.

GHRP-6 shows consistent promise for injury recovery in animal models across multiple injury types (stroke, kidney injury, wound healing, combined radiation-burn injury), but human evidence is extremely limited—only 2 RCTs exist and neither directly measures injury recovery outcomes in the primary endpoint. Efficacy in humans remains unproven.

Hexarelin shows consistent cardioprotective effects against ischemia-reperfusion injury in multiple animal models, but lacks any human RCT or robust human clinical trial evidence. Efficacy is demonstrated only in rodents and isolated heart preparations.

Melanotan-II shows promise for peripheral nerve regeneration in rat models, with one study demonstrating significantly accelerated sensory recovery after sciatic nerve crush injury. However, all evidence comes from animal studies; no human trials exist for injury recovery.

Humanin shows promise for injury recovery through mitochondrial protection and anti-inflammatory mechanisms in animal and cell culture models, but no human RCTs exist demonstrating clinical efficacy for injury recovery specifically.

GDF11 shows consistent benefits for injury recovery in animal models of stroke and myocardial infarction, with emerging human RCT data suggesting promise for stroke recovery. However, efficacy remains unproven in humans, and mechanistic studies reveal contradictory effects on tissue regeneration depending on organ context.

VIP shows promise for injury recovery through mechanistic studies in animal models and tissue culture, but human evidence is limited to one small RCT in corneal injury and observational data. Efficacy in humans remains plausible but unproven.

Thymalin shows plausible benefits for injury recovery based on human observational studies and animal models, but evidence remains preliminary. No randomized controlled trials exist, and human studies lack placebo controls and have small sample sizes.

Cortagen shows promise for nerve regeneration in animal models, with one rat study demonstrating 27-40% improvements in nerve growth rate and conduction velocity. However, no human trials exist, and efficacy in humans remains unproven.

Vilon shows plausible effects on tissue regeneration and cellular function in animal models, but efficacy in humans for injury recovery remains unproven. All evidence comes from animal studies with no human trials.

IGF-1 LR3 shows promise for injury recovery in animal models, particularly for nerve regeneration and volumetric muscle loss, but no human clinical trials exist to establish efficacy in humans. Evidence remains preliminary and limited to rodent studies.

MGF shows consistent mechanistic effects on injury recovery across animal and cell studies, but human evidence is limited to 1 RCT (cardiac) and 4 observational studies in specific tissues. Efficacy is plausible but not yet proven in humans for general injury recovery.

GLP-1 receptor agonists show mechanistic promise for injury recovery through anti-inflammatory, bone metabolism, and wound healing pathways in preclinical and early clinical studies, but efficacy in humans remains largely unproven with only observational data and no RCTs demonstrating clinical benefit for acute injury recovery.

One small human observational study (n=26) suggests topical Argireline may improve skin appearance and hydration in patients with scars and skin disorders, but efficacy for injury recovery is not proven—the study lacked placebo control, randomization, and objective outcome measures.

Omega-3 fatty acids show plausible mechanisms for injury recovery through anti-inflammatory and pro-resolving effects, but human evidence remains limited and inconsistent. Most positive findings come from mechanistic studies, animal models, and small human trials; large-scale human RCTs demonstrating clear clinical benefit for injury recovery are absent.

Berberine shows consistent efficacy for injury recovery in animal models, particularly for diabetic wound healing and bone regeneration, but human evidence is limited to one case report and observational studies without rigorous controls. Efficacy in humans remains plausible but unproven.

Resveratrol shows promise for injury recovery in animal models through anti-inflammatory and antioxidant mechanisms, but human evidence is limited to a single small RCT (n=36) demonstrating modest improvements in muscle recovery after plyometric exercise. Efficacy in humans remains plausible but unproven.

NMN shows plausible benefits for injury recovery through NAD+ restoration and mitochondrial support in animal models and in-vitro studies, but human efficacy evidence is absent. No human RCTs for injury recovery exist in the literature reviewed.

Alpha-lipoic acid shows promise for injury recovery primarily through antioxidant and anti-inflammatory mechanisms, but evidence is limited to one small human RCT in a specialized context (wound healing during hyperbaric oxygen therapy) and multiple animal studies. Efficacy in general injury recovery is plausible but not proven in humans.

Vitamin K2 shows plausible mechanisms for bone healing and recovery through enhanced osteogenesis in laboratory and animal models, but human evidence for injury recovery is very limited and mostly null. The single human RCT on exercise recovery found no clear benefit for muscle damage markers.

Tongkat Ali shows promise for bone health and fracture healing in animal models, but there is no human clinical evidence demonstrating efficacy for injury recovery. All mechanistic support comes from in-vitro and animal studies.

Boron shows promising effects on injury recovery in animal models, particularly for cardiac repair and wound healing, but human efficacy remains unproven with only one small RCT available. Current evidence is emerging but insufficient to establish clinical benefit in humans.

Milk thistle shows plausible mechanisms for injury recovery through antioxidant and anti-inflammatory effects, but human evidence is limited to 3 small RCTs with mixed or incomplete results. Efficacy for injury recovery is not yet proven.

Rhodiola rosea and its active compound salidroside show consistent promise for injury recovery in animal models, particularly for bone healing, wound healing, and tissue regeneration. However, human evidence is minimal (only 1 RCT directly studying injury recovery), limiting definitive proof of efficacy in humans.

Maca root shows plausible mechanisms for injury recovery based on animal and in-vitro studies demonstrating wound healing acceleration and anti-inflammatory effects, but human efficacy remains unproven with only one small observational study and one failed RCT available.

Elderberry shows plausible potential for wound healing based on consistent animal and in-vitro evidence demonstrating anti-inflammatory and antioxidant effects, but human efficacy remains unproven—no RCTs exist for this indication.

Green tea extract (EGCG) shows consistent beneficial effects on injury recovery in animal models and emerging human evidence, primarily for wound healing and tissue regeneration. However, only 2 human RCTs exist, both specifically for radiation-induced intestinal injury and interstitial lung disease—not generalized injury recovery—limiting proof of broad efficacy in humans.

Psyllium husk shows plausible potential for wound healing and injury recovery based on animal studies and in vitro evidence, but human efficacy remains unproven. Only one human observational study exists, and it focused on diabetic wound healing specifically rather than general injury recovery.

Spirulina shows consistent positive effects on wound healing in animal models and one small human RCT, but efficacy in humans remains unproven due to limited human evidence. The mechanism appears robust (antioxidant, anti-inflammatory, angiogenic), but clinical translation is preliminary.

Fenugreek shows consistent wound-healing effects in animal models and preliminary human observational studies, but lacks rigorous human RCTs. Efficacy is plausible based on mechanism and animal data, but not yet proven in humans.

Glucosamine + Chondroitin shows promise for injury recovery in animal and in-vitro models through enhanced collagen synthesis and cartilage repair, but human evidence for injury recovery specifically is minimal and inconclusive. The single human RCT available is a small animal study (rabbits), not humans.

Vitamin B Complex shows plausible but unproven efficacy for injury recovery. Evidence is limited to small human studies, animal models, and mechanistic observations; no large-scale RCTs demonstrate clinical benefit for general injury recovery.

Vitamin E shows plausible mechanisms for injury recovery (antioxidant, anti-inflammatory, wound healing promotion) supported by animal studies and mechanistic research, but human efficacy evidence is sparse and limited to small or specialized populations. No large-scale human RCTs demonstrate clinically meaningful injury recovery benefits.

Iron supplementation shows plausible benefits for injury recovery based on mechanistic studies and observational evidence in specific populations (burn patients, athletes), but rigorous human RCT evidence directly demonstrating efficacy for general injury recovery is lacking. Most studies focus on iron's role in endurance capacity, muscle damage markers, or recovery in specialized contexts rather than injury healing per se.

Selenium shows promise for injury recovery through antioxidant and anti-inflammatory mechanisms in animal and cell models, but human evidence is limited to one negative RCT in cardiac surgery patients and observational studies. Efficacy in humans for injury recovery is not yet proven.

Biotin shows mechanistic promise for injury recovery through effects on remyelination, inflammation reduction, and tissue repair in animal models, but there is no human evidence demonstrating efficacy for this specific goal.

Fisetin shows promise for injury recovery through senolytic and anti-inflammatory mechanisms in animal and in vitro models, but human efficacy evidence is extremely limited. Only one human RCT exists (topical wound healing in diabetic mice converted to humans), with no large-scale human trials demonstrating clinical benefit for common injury types.

Spermidine shows plausible mechanisms for injury recovery through autophagy enhancement and anti-inflammatory effects, but human evidence is minimal—only 1 RCT exists, and recent animal studies show mixed or null results for muscle recovery specifically.

Urolithin A shows mechanistic promise for injury recovery in animal models through mitophagy and mitochondrial homeostasis, but human efficacy for injury recovery remains unproven. One human RCT in distance runners found no significant performance improvements despite positive mitochondrial biomarker trends.

Sulforaphane shows consistent mechanistic promise for injury recovery across animal and cell studies, particularly for skeletal muscle and tendon repair through Nrf2 and JAK/STAT pathway activation. However, no human RCTs exist to confirm clinical efficacy—all human evidence is observational or mechanistic.

Astaxanthin shows potential for reducing subjective muscle soreness and supporting recovery from exercise-induced muscle damage in humans, but evidence remains limited to a single small human trial. Animal data suggests stress-mitigation effects, but efficacy for injury recovery in humans is not yet proven.

Glutathione shows promise for injury recovery in animal models, with demonstrated neuroprotective effects in spinal cord injury and cardioprotective effects in ischemia-reperfusion injury. However, no human RCTs exist for injury recovery, and the single human observational study is mechanistic rather than efficacy-focused.

TUDCA shows consistent cytoprotective and anti-inflammatory effects in animal models of spinal cord injury and other acute injuries, but human efficacy for injury recovery remains unproven. Only 1 human RCT exists, and multiple animal studies show transient benefits that do not persist long-term.

Nattokinase shows plausible promise for injury recovery through anti-inflammatory and thrombolytic mechanisms demonstrated in animal and in-vitro models, but human efficacy evidence is limited to a single RCT focused on stroke recovery with results not fully detailed in the abstract.

One human RCT found that Shilajit supplementation upregulated extracellular matrix (ECM) genes in skeletal muscle, suggesting potential support for muscle structural adaptation. However, no direct efficacy measures for injury recovery (healing speed, pain reduction, functional restoration) were assessed, and results remain mechanistic rather than clinically validated.

Colostrum shows plausible mechanisms for injury recovery through growth factors, immunomodulation, and tissue repair signaling, but human efficacy evidence is extremely limited. Only one small human study and one animal wound-healing study directly tested colostrum for injury/wound recovery; most evidence is mechanistic or tangential.

Cordyceps shows promising effects on muscle recovery and tissue repair mechanisms in one human RCT and multiple animal models, but efficacy for injury recovery is not yet proven in humans. The single human trial demonstrated accelerated stem cell recruitment and reduced muscle damage after exercise, but larger, independent human studies are needed to confirm clinical significance.

Reishi (Ganoderma lucidum) shows consistent mechanistic promise for injury recovery in animal models and in-vitro systems, particularly for wound healing and tissue regeneration. However, only 1 small human RCT exists, and no human studies specifically demonstrate clinically meaningful injury recovery outcomes.

Chaga mushroom extract shows promise for muscle injury recovery in animal models through AKT-dependent mechanisms that enhance myogenesis and muscle regeneration. However, no human clinical trials exist for this specific application, limiting proof of efficacy to pre-clinical evidence.

Epicatechin shows consistent promise for muscle repair and regeneration in animal models through upregulation of myogenic proteins and mitochondrial biogenesis, but human evidence is limited to one small open-label study (n=7) in Becker muscular dystrophy without a control group. Efficacy in humans for injury recovery remains plausible but unproven.

Pterostilbene shows promise for injury recovery across multiple models, but human evidence is limited to one small RCT that found no benefit for muscle injury recovery in elderly adults. Most supporting data comes from animal studies and mechanistic work in cell cultures.

MSM shows plausible benefits for injury recovery through improved inflammatory response and immune modulation in humans, but evidence remains preliminary with only 1 small RCT (n=10) and 1 observational study (n=15) demonstrating efficacy in exercise recovery contexts.

Stinging nettle shows promise for wound healing in animal models with consistent positive effects on closure rates and tissue regeneration, but human evidence is limited to one small self-experiment on laser burns and observational diabetes data. Efficacy in humans for injury recovery remains plausible but unproven.

Mucuna pruriens shows preliminary promise for injury recovery based on one human RCT demonstrating wound healing benefits and two animal studies suggesting neuroprotective effects post-injury, but efficacy remains unproven in humans due to limited study volume and mixed results.

Ecdysterone shows plausible benefits for injury recovery in animal models and cell studies, with evidence of enhanced bone healing, wound healing, and muscle recovery. However, only 1 true human RCT exists (glucocorticoid-induced bone loss), and most injury recovery data comes from animal studies or mechanistic research, making human efficacy unproven.

Turkesterone shows consistent effects on red blood cell regeneration and liver recovery in rodent models, but no human trials exist for injury recovery specifically. Efficacy in humans remains unproven.

Cistanche compounds show consistent effects on injury-related outcomes in animal models, particularly for bone regeneration and neuropathic injury recovery, but evidence is limited to one small human RCT on stroke. Efficacy is plausible but not proven in humans for injury recovery.

Echinacea shows plausible potential for injury/wound recovery based on 2 small human RCTs and mechanistic animal studies, but evidence is limited by small sample sizes and lack of independent replication. Efficacy is suggested but not conclusively proven for this specific goal.

Schisandra shows promise for spinal cord injury recovery through anti-inflammatory and anti-apoptotic mechanisms in animal and cell models, but evidence is limited to preclinical studies with no human clinical trials demonstrating efficacy.

CLA shows promise for injury recovery in animal models, particularly for fracture healing and neural repair, but human evidence is limited to one small RCT with negative findings on brain injury recovery. Efficacy in humans remains unproven.

Methylene blue shows promise for injury recovery in animal models and limited human studies, particularly for wound healing and post-surgical fibrosis prevention, but rigorous human evidence is lacking and efficacy in humans remains unproven.

Lithium orotate has not been directly tested for injury recovery in humans. Limited animal evidence suggests lithium may support nerve regeneration and cellular recovery through GSK-3β inhibition and neuroprotective pathways, but no clinical efficacy data exists for this specific goal.

Pregnenolone shows promise for nerve injury recovery in animal models through neuroprotective and remyelination mechanisms, but human efficacy for injury recovery remains unproven. No human RCTs exist; evidence is limited to mechanistic studies, observational data on pain (not recovery), and animal models.

Rapamycin shows promise for injury recovery through mTOR pathway inhibition and enhanced autophagy in animal models and mechanistic studies, but lacks rigorous human RCT evidence demonstrating clinical efficacy for injury recovery specifically.

D-ribose has shown promise in animal models of ischemic injury (stroke, cardiac ischemia) by facilitating ATP recovery, but human efficacy for injury recovery remains unproven. Only 4 human RCTs exist in this dataset, none of which directly demonstrate clinical benefit in injury recovery.

Astragalus shows promise for injury recovery in animal models and early human studies, with consistent effects on muscle repair, wound healing, and bone regeneration. However, human evidence remains limited (3 RCTs total), with small sample sizes and short follow-up periods, making efficacy plausible but not yet conclusively proven in humans.

Butyrate shows promise for injury recovery in animal models and mechanistic studies, with emerging evidence from a few human trials. However, efficacy in humans remains unproven due to limited high-quality RCT data and reliance on animal/in-vitro studies.

Lion's Mane shows consistent neuroprotective and nerve regeneration effects in animal models, particularly for peripheral nerve injury recovery, but lacks human RCT evidence. Current evidence is limited to mechanistic studies, animal models, and reviews, with no rigorous human trials demonstrating efficacy for injury recovery.

Bacopa monnieri shows emerging promise for injury recovery, with evidence primarily from animal studies and in-vitro research demonstrating wound healing acceleration and nerve regeneration support. However, only one human RCT exists (cardiac injury model), and no rigorous human trials specifically assess recovery from musculoskeletal or soft-tissue injuries.

Phosphatidylserine is a biomarker and signaling molecule involved in injury recovery processes, but direct evidence for its use as a therapeutic supplement for injury recovery in humans is absent. Most evidence comes from mechanistic studies in animal models or cell-based research showing PS involvement in immune responses, tissue repair pathways, and apoptotic clearance.

Panax ginseng shows plausible mechanisms for injury recovery (wound healing, anti-inflammatory, antioxidant effects) supported by multiple animal and in-vitro studies, but human efficacy for injury recovery remains largely unproven. Only one human RCT exists (on myocardial infarction, not general injury), and most evidence is mechanistic or preclinical.

Huperzine A shows promise for injury recovery in animal models of traumatic brain injury and intracerebral hemorrhage, with improvements in cognition, neuroinflammation, and mitochondrial protection. However, the only human RCT found no difference between Huperzine A and placebo on cognitive outcomes, making efficacy in humans unproven.

PQQ shows consistent neuroprotective and anti-inflammatory effects across multiple animal models of injury, but only 2 human RCTs exist—one for ischemic stroke and one for sciatic nerve regeneration—limiting definitive proof of efficacy in humans. Animal data is robust but does not substitute for larger, well-powered human trials.

Piracetam shows plausible but unproven efficacy for injury recovery based primarily on animal studies and small human observational trials. Only one human RCT directly evaluated piracetam for TBI, and it was a study protocol rather than completed results.

Aniracetam shows promise for cognitive recovery after traumatic brain injury in animal models, but efficacy is dependent on continued drug administration and unproven in humans. One animal study suggests cognitive benefits, but another raises serious concerns about false positive reporting in neuroprotection research.

Oxiracetam shows plausible promise for cognitive recovery after brain injury based on one small human observational study and one animal model, but efficacy is NOT yet proven in humans. An RCT is currently underway but results are not yet available.

L-theanine shows promise for injury recovery in animal models through anti-inflammatory and antioxidant mechanisms, but no human clinical trials exist to prove efficacy in human injury recovery.

L-tyrosine shows plausible but unproven efficacy for injury recovery. Only one animal study directly tested L-tyrosine supplementation for stress-related outcomes; no human trials for injury recovery exist in this dataset.

Glycine shows plausible benefits for injury recovery based on consistent animal and mechanistic evidence, particularly for collagen synthesis and wound healing, but no human RCTs or clinical trials have been conducted to prove efficacy in injured populations.

5-HTP shows plausible potential for spinal cord injury recovery based on consistent animal studies demonstrating respiratory and locomotor improvements, but no human clinical trials exist to prove efficacy in injury recovery.

GABA shows mechanistic promise for injury recovery through animal studies demonstrating roles in axon regeneration and post-stroke neuroplasticity, but human efficacy for injury recovery remains largely unproven with only observational data and no rigorous RCTs directly testing GABA supplementation for this goal.

Beta-alanine (primarily via carnosine, its conjugate with histidine) shows plausible benefits for injury recovery in animal models through antioxidant and anti-inflammatory mechanisms, but human evidence is limited to one small observational hypothesis and one equine study. Efficacy in humans remains unproven.

D-Aspartic acid shows promise for myelin repair and neurological recovery based primarily on animal studies, but human efficacy for injury recovery remains unproven. One well-designed animal study demonstrated accelerated myelin recovery and improved motor coordination, but no rigorous human trials exist for this specific goal.

One human RCT found that Naomaitong (a traditional Chinese medicine containing tryptophan-related compounds) improved stroke recovery outcomes in humans, but this does not directly demonstrate that tryptophan supplementation itself is efficacious for injury recovery, as the study tested a complex herbal formula, not isolated tryptophan.

Lysine shows plausible mechanisms for supporting injury recovery through bone regeneration and tissue repair pathways, but evidence is limited to one in-vitro cell culture study and one animal model study. No human trials have evaluated lysine supplementation for injury recovery.

Larazotide shows promise for injury recovery through tight junction repair in one small human RCT and supportive in-vitro data, but efficacy is not yet proven. The human trial was very small (n=12) and focused on post-COVID inflammation rather than general injury recovery.

Cortistatin shows promise for injury recovery in animal models of stroke and autoimmune neuroinflammation, but no human efficacy studies exist. The only human evidence is observational in nature and focused on biocompatibility in tissue engineering scaffolds, not injury recovery outcomes.

Dulaglutide shows promise for injury recovery in animal models of wound healing and vascular injury, with mechanistic evidence of enhanced tissue repair. However, no human trials demonstrate efficacy for injury recovery, and the only human data is a case report of adverse kidney effects.

Exenatide shows promise for injury recovery in animal models of spinal cord injury through mechanisms like reducing inflammation and endoplasmic reticulum stress, but human evidence is limited to a single open-label trial in a different condition (multiple system atrophy) with no direct testing in acute injury recovery.

Ghrelin shows promise for injury recovery in animal models, with demonstrated effects on wound healing and colonic anastomosis repair. However, human efficacy for injury recovery remains unproven—only mechanistic reviews and one small human RCT on bone markers exist.

Matrixyl shows consistent positive effects on wound healing in animal models and cell studies, with evidence of increased collagen production and accelerated healing. However, no randomized controlled trials in humans exist to confirm efficacy—the single human study was observational only.

NA-Semax Amidate accelerated ulcer healing in a rat model, but no human clinical trials exist. Efficacy in humans for injury recovery remains unproven.

Nesfatin-1 shows promise for injury recovery in animal models, particularly for spinal cord injury and wound healing, but evidence is limited to animal studies and mechanistic research. No human clinical trials demonstrate efficacy for injury recovery.

NPY shows promise for injury recovery through mechanisms involving bone healing, wound healing, and pain modulation, but evidence remains primarily animal-based with only a handful of small human studies. Efficacy in humans is plausible but not yet proven.

Octreotide shows mixed effects on injury recovery: it impairs general wound healing in animal models but may benefit specific complications like pharyngocutaneous fistulas and esophageal perforations. No clear, consistent evidence of efficacy for injury recovery as a primary goal.

Orexin-A shows promise for promoting arousal and consciousness recovery after brain and spinal cord injuries in animal models, with consistent mechanistic support, but lacks rigorous human trials to confirm clinical efficacy.

P21 plays a regulatory role in neural stem cell proliferation and recovery after brain injury in animal models, but no human efficacy trials exist. Evidence is limited to mechanistic studies and animal injury models.

PACAP shows neuroprotective and nerve regeneration-promoting effects in multiple animal and limited human studies, but human efficacy for injury recovery remains largely unproven. Evidence is primarily mechanistic and observational rather than from controlled trials.

PTD-DBM shows promise for accelerating wound healing and reducing scarring in mouse models by blocking a negative regulator of the Wnt/β-catenin pathway. However, all evidence is from animal studies with no human trials, so efficacy in humans remains unproven.

Vosoritide (CNP analog) shows promising effects on bone repair and growth in animal models of genetic skeletal dysplasias, but no human efficacy trials for injury recovery have been published. Evidence is limited to preclinical studies in mice.

C-10 is a chemokine with demonstrated roles in inflammation and tissue repair, but evidence for injury recovery specifically comes only from animal studies and mechanistic reviews. No human clinical trials have evaluated C-10 for injury recovery outcomes.

Alpha-ketoglutarate (AKG) shows promise for injury recovery in multiple animal models through enhanced stem cell function and metabolic reprogramming, but human evidence is limited to a single small RCT on pressure ulcers with inconclusive results due to baseline imbalance.

Folate shows promise for spinal cord injury recovery and axonal regeneration based on multiple animal studies and one human observational study, but no human randomized controlled trials have demonstrated efficacy. The mechanism is plausible but clinical benefit in humans remains unproven.

Luteolin shows promise for injury recovery based on multiple animal studies and a few small human trials, but evidence of actual efficacy in humans remains limited. Most positive findings come from laboratory and animal models rather than rigorous human clinical trials.

Ginger shows promising effects on wound healing and bone/tissue regeneration in animal models, with consistent mechanistic findings around inflammation reduction and growth factor upregulation. However, no human clinical trials exist for injury recovery, leaving efficacy in real patients unproven.

Cinnamon shows promise for injury recovery through antioxidant and anti-inflammatory mechanisms demonstrated in animal models, particularly for diabetic wound healing, but no human clinical trials have tested its efficacy for this specific goal.

Vitamin K1 shows biochemical effects on bone metabolism markers in humans, but evidence for actual improvement in injury recovery is limited and inconsistent. Most positive findings relate to bone turnover markers rather than clinical outcomes like fracture healing or recovery speed.

Yellow Dock (Rumex abyssinicus) shows promising wound healing and anti-inflammatory effects in animal models, but no human studies exist. Efficacy in humans remains unproven.

Manuka honey shows antimicrobial activity and potential for wound healing in animal and in-vitro studies, but no human clinical trials exist to prove efficacy for injury recovery.

Black pepper (piperine) shows promise for reducing inflammation and oxidative stress in injury/recovery contexts based on animal studies, but there is no human evidence demonstrating efficacy for actual injury recovery outcomes.

Moringa oleifera shows consistent wound-healing benefits in animal models and in-vitro studies through antioxidant and anti-inflammatory mechanisms, but evidence from human clinical trials is extremely limited (only 1 small human RCT on dental pulp repair), making efficacy in humans unproven.

DHEA shows promise for muscle recovery from exercise-induced damage in one small human RCT, but evidence for injury recovery is largely limited to observational studies of steroid response patterns and mechanistic reviews. No human RCTs have tested DHEA supplementation in actual trauma or injury patients.

Caffeine shows mixed effects on injury recovery in the limited human evidence available. One RCT found modest improvements in muscle torque after exercise-induced damage (6.8-9.4%), but another study suggested caffeine may increase muscle injury markers during intense exercise. No clear evidence that caffeine accelerates actual tissue repair or functional recovery from injury.

Custom orthotics show plausibility for injury recovery based on three small observational studies, but no RCTs exist and efficacy is not definitively proven. Evidence is limited to case reports and small observational studies without control groups or rigorous outcome measures.

CJC-1295 is mentioned theoretically as a growth hormone secretagogue that may activate IGF-1 signaling relevant to muscle repair, but no clinical efficacy has been demonstrated. Both available abstracts are reviews without any human or animal trial data specific to injury recovery outcomes.

Selank is mentioned theoretically as a neuroactive peptide that may enhance recovery pathways, but there is zero empirical evidence — no human trials, no animal studies, and no efficacy data — demonstrating that it actually works for injury recovery.

Epithalon has not been studied in humans for injury recovery. Evidence is limited to one in-vitro cell study showing antioxidant effects on retinal wound healing, and mechanistic discussion in a review article. No proven efficacy in any living organism exists.

DSIP is mentioned as a recovery-enhancing peptide with potential relevance to injury recovery through circadian and mitochondrial regulation, but no clinical efficacy data exists for this application. All available evidence is from reviews discussing theoretical mechanisms without human or animal trials demonstrating actual injury recovery benefits.

Dihexa is mentioned theoretically as a neuroactive peptide that may enhance BDNF and HGF/c-Met pathways relevant to neuroplasticity in a review of orthopaedic peptides, but there are no actual clinical or animal efficacy studies demonstrating that dihexa works for injury recovery.

Kisspeptin has not been studied for injury recovery in humans. All evidence is mechanistic (animal and in-vitro), showing roles in bone formation, endometrial regeneration, and cellular senescence — but none directly address injury recovery as a clinical goal.

No human evidence exists for Melanotan 1 in injury recovery. The abstracts discuss melanocortin receptor biology and mention related compounds (afamelanotide, setmelanotide, bremelanotide) for dermatological conditions, but provide no clinical data on Melanotan 1 specifically for injury recovery.

Follistatin 344 has not been studied for injury recovery in any human trials. A single rat study shows that follistatin levels correlate with muscle recovery after nerve injury, but the study measured follistatin as a biomarker of atrophy, not as a therapeutic intervention.

FOXO4-DRI has only been studied in vitro and in animal models for injury recovery contexts; no human clinical trials exist demonstrating efficacy for injury recovery specifically. Evidence is limited to mechanistic studies showing senescent cell clearance in diseased tissues.

Pinealon is mentioned as a theoretical recovery-enhancing peptide targeting circadian and mitochondrial regulators in a 2026 review, but there are no clinical trials, animal studies, or in-vitro data specifically demonstrating its efficacy for injury recovery in the provided literature.

Bronchogen has no demonstrated efficacy for human injury recovery. The only available study examined gene expression in tobacco plant cell cultures, which is irrelevant to injury recovery in humans.

Cartalax has only been studied in skin fibroblast cell culture with no human or animal trials. While in-vitro results suggest potential benefits for cellular aging markers, efficacy in actual injury recovery is not demonstrated.

5-Amino-1MQ has not been studied for injury recovery in any published research. The single available study examined its anti-cancer effects in cervical cancer cells in vitro, which is unrelated to the injury recovery goal.

Prostatilen has not been studied for injury recovery in humans. A single animal study shows that prostate-derived polypeptides stimulated cell growth in rat tissue cultures, but this in-vitro effect does not constitute evidence of efficacy for injury recovery in any living organism.

No human evidence supports quercetin for injury recovery. Only one animal study (in rats with alcohol-induced liver damage) and one in-vitro mechanistic study exist, neither directly assessing injury recovery outcomes.

Saw palmetto has not been studied for injury recovery in humans. The available evidence focuses entirely on androgenetic alopecia and benign prostatic hyperplasia, with only animal models and no human trials demonstrating any efficacy for injury recovery specifically.

No evidence supports iodine supplementation for injury recovery. Available studies document iodine toxicity (retinal damage from overdose) and thyroid inflammation, with no data on injury healing or recovery outcomes.

Chromium has not been proven effective for injury recovery in humans. The single human case report showed chromium use in a septic shock patient, but this is anecdotal and does not establish efficacy for injury recovery. Animal studies show mixed and often negative results.

Only a single animal study exists for lactoferrin and injury recovery, showing prevention of UV-induced corneal damage in rats when applied topically before injury. No human evidence supports efficacy for injury recovery.

Tribulus terrestris shows no proven efficacy for injury recovery in humans. The 13 articles contain zero human RCTs or human observational studies specifically testing Tribulus for injury/wound healing as a primary outcome, and one human case report documents severe hepatotoxicity.

No evidence supports valerian root for injury recovery. The single available study examined valeric acid (a valerian component) for liver cancer in mice, which is entirely unrelated to the injury recovery goal.

No evidence supports Kava for injury recovery. The only human data available documents severe hepatotoxicity, including liver failure and deaths, making Kava contraindicated for any therapeutic use.

Forskolin has not been demonstrated to improve injury recovery in humans. The only human case report involved autologous Schwann cells where forskolin was used as a cell culture supplement, not as a therapeutic agent for recovery itself.

Betaine HCl has not been studied for injury recovery in humans. Available evidence is limited to mechanistic reviews and animal studies exploring betaine's role in cellular metabolism, with no direct evidence demonstrating efficacy for injury recovery or tissue repair.

Centrophenoxine has not been proven effective for injury recovery in humans. Only one animal study exists, showing cellular regeneration effects in senile rat brain tissue—findings that do not directly translate to injury recovery or clinical utility.

9-ME-BC shows neuroprotective and regenerative properties for dopaminergic neurons in cell culture, but there is no human evidence or animal studies demonstrating efficacy for injury recovery. The available data consists of one in-vitro study and one review with no clinical validation.

DMAE has not been proven effective for injury recovery in humans. Available evidence is limited to one observational case report using DMAE as part of a multi-modal treatment for scars, plus mechanistic studies in cell culture and animal models unrelated to injury recovery.

L-Citrulline has not been demonstrated to improve injury recovery in humans. The abstracts provided contain mechanistic studies on nitric oxide metabolism, one in-vitro cell culture study on chemotherapy-induced mucositis, and animal/poultry studies on temperature regulation—none directly testing recovery from physical injury or trauma in human subjects.

No human evidence exists that retatrutide improves injury recovery. The three available abstracts are reviews that discuss bone health in obesity and diabetes contexts, not injury recovery, and contain no direct efficacy data for retatrutide specifically.

Tirzepatide has not been studied for injury recovery in humans. Available evidence is limited to mechanistic studies in cell culture and animal models suggesting potential bone and tissue effects, but no efficacy data exists for wound healing, fracture recovery, or any injury recovery outcomes in humans.

Cagrilintide is mentioned only incidentally in a nutritional guidance article about GLP-1 agonists and bariatric surgery; no studies directly examine cagrilintide's efficacy for injury recovery.

IGF-1 DES has not been studied for injury recovery in humans. Only in-vitro cell culture work and one mechanistic review exist, showing no demonstrated efficacy for injury recovery in any living organism.

Lanreotide has not been studied for injury recovery in humans. The available evidence consists of animal studies and in vitro work examining related compounds (angiopeptin, somatostatin analogues) for vascular injury and tumor-related outcomes, but none directly address lanreotide's efficacy for injury recovery.

Linaclotide has not been proven effective for injury recovery in humans. The one animal study showed it may help reduce intestinal damage markers in a specific rat model of severe pancreatitis, but no human efficacy data exists for this goal.

Lixisenatide has not been studied for injury recovery in humans or animals. The single available abstract examines plaque composition in atherosclerotic rabbits, which is unrelated to injury recovery.

Pemvidutide has not been studied for injury recovery in any of the available evidence. The 18 abstracts focus on metabolic, glycemic, and bone health effects in diabetes and obesity contexts, with no studies examining wound healing, fracture recovery, tissue repair, or any injury-related outcomes.

Peptide YY has been studied in relation to bone metabolism and tissue repair, but there is no evidence that it improves injury recovery in humans. The available data shows PYY's role in bone remodeling—primarily as a negative regulator of bone formation—and mechanistic associations with metabolic markers, but no clinical trials demonstrate efficacy for injury recovery.

No evidence demonstrates that pramlintide improves injury recovery. The abstracts discuss pramlintide's effects on Alzheimer's disease, diabetes management, bone metabolism, and migraine—not injury recovery.

Setmelanotide has not been studied for injury recovery in humans or animals. The available literature discusses its use for obesity and genetic forms of hyperphagia, with only passing mention of potential bone/muscle effects in the context of weight loss.

No human evidence exists that Survodutide improves injury recovery. The 18 abstracts retrieved discuss GLP-1 agonists and related compounds primarily for diabetes, obesity, and metabolic disease—not injury recovery. One animal study examined traumatic brain injury, but Survodutide itself was not tested.

Thymopentin shows no proven efficacy for injury recovery. Two animal studies found it actually impaired wound healing, while one animal study found no effect. The only human data comes from a radiation therapy context unrelated to typical injury recovery.

No human evidence demonstrates that thymulin improves injury recovery. Animal studies show thymulin actually impairs wound healing, contradicting its use for this goal.

NAD+ has been studied extensively for aging and age-related diseases in animal models and mechanistic reviews, but there is no human evidence demonstrating that NAD+ supplementation actually improves injury recovery outcomes. All provided abstracts discuss NAD+ metabolism in aging and disease contexts but none specifically measure injury recovery endpoints in human subjects.

Manganese is mentioned as a suggested intervention in one rare genetic disorder case and restored bacterial growth in a laboratory setting, but there is no evidence of efficacy for injury recovery in humans.

Vitamin B1 has not been proven to improve injury recovery in humans. The reviewed literature focuses on B1 deficiency treatment and metabolic complications, not on B1 supplementation as an injury recovery intervention.

Vitamin B2 has not been studied for injury recovery in humans. The only human RCT examined sickle cell disease markers, not injury recovery, and a review article mentions B2 as a nutrient in sea cucumbers without addressing injury recovery.

Vitamin B5 (pantothenic acid) supplementation showed mixed results in a single animal study, with significant improvements in deep wound strength and fibroblast proliferation, but only minor non-significant improvements in skin strength. No human evidence exists.

Only one animal study (rat model) exists for lycopene and injury recovery; no human evidence demonstrates that lycopene actually improves injury recovery outcomes.

Lutein has not been demonstrated to improve injury recovery in any study. The available evidence consists only of reviews and one animal study showing lutein did not enhance wound healing or immune function in developing chameleons.

MCT oil has not been demonstrated to improve injury recovery in humans. Available evidence is limited to animal studies of liver regeneration and one in-vitro cardiac toxicity model, with no human trials specifically testing MCT oil for injury recovery.

Zeaxanthin shows no evidence of efficacy for injury recovery. Available studies examine only retinal health and light-induced toxicity in eye cells, not injury recovery, and suggest zeaxanthin may actually exacerbate photodamage under certain conditions.

There is no evidence that beetroot juice improves injury recovery. The single available study examined vascular and inflammatory markers in healthy older adults, not injury recovery outcomes.

Sea moss extract has not been studied for injury recovery in humans. The available evidence consists only of in-vitro and review studies examining polysaccharides from red seaweeds, with no proven efficacy demonstrated in any living organism for this specific goal.

Kelp has not been studied for injury recovery in humans. The only available evidence is from a single animal study examining thyroid health under iodine deficiency, which is unrelated to injury recovery.

There is no evidence that chlorophyll improves injury recovery. The single available study examined chlorophyllin's effect on DNA damage from a carcinogen in mice, not injury recovery.